ID

29139

Description

A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione; ODM derived from: https://clinicaltrials.gov/show/NCT00743002

Link

https://clinicaltrials.gov/show/NCT00743002

Keywords

Versions (1)
  1. 2/28/18 2/28/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 28, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diabetes Mellitus, Type 2 NCT00743002

English

Eligibility Diabetes Mellitus, Type 2 NCT00743002

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes for at least 6 months
Description

Diabetes Mellitus, Non-Insulin-Dependent

Data type

boolean

Alias
UMLS CUI [1]
C0011860
treated with metformin and/or thiazolidinediones with stable dose for at least 3 months
Description

Metformin Dose Stable | Thiazolidinediones Dose Stable

Data type

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C1257987
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
bmi of 21-45 kg/m2, inclusive
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
hba1c level of 7.50 - 10.00%, inclusive
Description

Glucohemoglobin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0202054
if a female of childbearing potential, willing to utilize contraception from screening through 4 weeks after the last dose of study drug
Description

Childbearing Potential Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with insulin, sulfonylurea, dpp-4 inhibitors, symlin® and/or glp-1 analogues ≤ 3 months prior to the screening
Description

Insulin | Sulfonylurea | Dipeptidyl-Peptidase IV Inhibitors | Symlin | GLP-1 Analogue

Data type

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2]
C0038766
UMLS CUI [3]
C1827106
UMLS CUI [4]
C1174780
UMLS CUI [5]
C3273809
severe hypoglycemia ≤ 60 days prior to the screening visit or currently diagnosed with having hypoglycemia unawareness
Description

Hypoglycemia Severe | Loss of hypoglycemic warning

Data type

boolean

Alias
UMLS CUI [1,1]
C0020615
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C0342317
history of peptic ulcer(s) and/or gastrointestinal bleeding/perforation
Description

Gastric ulcer | Gastrointestinal Hemorrhage | Gastrointestinal perforation

Data type

boolean

Alias
UMLS CUI [1]
C0038358
UMLS CUI [2]
C0017181
UMLS CUI [3]
C0151664
previous gastric surgery, including gastric bypass, or has gastric bypass/other major surgery planned to occur during the 10 month trial
Description

Operation on stomach | Gastric Bypass | Gastric Bypass Planned | Major surgery Planned

Data type

boolean

Alias
UMLS CUI [1]
C0192398
UMLS CUI [2]
C0017125
UMLS CUI [3,1]
C0017125
UMLS CUI [3,2]
C1301732
UMLS CUI [4,1]
C0679637
UMLS CUI [4,2]
C1301732
myocardial infarction within the last 2 years, current congestive heart failure with nyha class 2 or greater, or chronic atrial fibrillation
Description

Myocardial Infarction | Congestive heart failure New York Heart Association Classification | Chronic atrial fibrillation

Data type

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2,1]
C0018802
UMLS CUI [2,2]
C1275491
UMLS CUI [3]
C0694539
current clinically significant and/or chronic illness
Description

Illness Clinical Significance | Chronic disease

Data type

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C2826293
UMLS CUI [2]
C0008679
takes regular courses of non-steroidal anti-inflammatory drugs (nsaids). if these medications are discontinued upon starting screening procedures and are not planned to be regularly used during the trial, the patient will be allowed to enter the study
Description

Non-Steroidal Anti-Inflammatory Agents Regular

Data type

boolean

Alias
UMLS CUI [1,1]
C0003211
UMLS CUI [1,2]
C0205272
use of systemic corticosteroids (oral, suppository, injected). use of inhaled or topical corticosteroids is permitted
Description

CORTICOSTEROIDS FOR SYSTEMIC USE Oral | CORTICOSTEROIDS FOR SYSTEMIC USE Suppository | CORTICOSTEROIDS FOR SYSTEMIC USE Injection | CORTICOSTEROIDS FOR SYSTEMIC USE Inhalation allowed | Topical corticosteroids allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C3653708
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C3653708
UMLS CUI [2,2]
C0038854
UMLS CUI [3,1]
C3653708
UMLS CUI [3,2]
C1828121
UMLS CUI [4,1]
C3653708
UMLS CUI [4,2]
C0205535
UMLS CUI [4,3]
C0683607
UMLS CUI [5,1]
C0304604
UMLS CUI [5,2]
C0683607
Back to the top of the page

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT00743002

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes for at least 6 months
boolean
C0011860 (UMLS CUI [1])
Metformin Dose Stable | Thiazolidinediones Dose Stable
Item
treated with metformin and/or thiazolidinediones with stable dose for at least 3 months
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C1257987 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Body mass index
Item
bmi of 21-45 kg/m2, inclusive
boolean
C1305855 (UMLS CUI [1])
Glucohemoglobin measurement
Item
hba1c level of 7.50 - 10.00%, inclusive
boolean
C0202054 (UMLS CUI [1])
Childbearing Potential Contraceptive methods
Item
if a female of childbearing potential, willing to utilize contraception from screening through 4 weeks after the last dose of study drug
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Insulin | Sulfonylurea | Dipeptidyl-Peptidase IV Inhibitors | Symlin | GLP-1 Analogue
Item
treatment with insulin, sulfonylurea, dpp-4 inhibitors, symlin® and/or glp-1 analogues ≤ 3 months prior to the screening
boolean
C0021641 (UMLS CUI [1])
C0038766 (UMLS CUI [2])
C1827106 (UMLS CUI [3])
C1174780 (UMLS CUI [4])
C3273809 (UMLS CUI [5])
Hypoglycemia Severe | Loss of hypoglycemic warning
Item
severe hypoglycemia ≤ 60 days prior to the screening visit or currently diagnosed with having hypoglycemia unawareness
boolean
C0020615 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0342317 (UMLS CUI [2])
Gastric ulcer | Gastrointestinal Hemorrhage | Gastrointestinal perforation
Item
history of peptic ulcer(s) and/or gastrointestinal bleeding/perforation
boolean
C0038358 (UMLS CUI [1])
C0017181 (UMLS CUI [2])
C0151664 (UMLS CUI [3])
Operation on stomach | Gastric Bypass | Gastric Bypass Planned | Major surgery Planned
Item
previous gastric surgery, including gastric bypass, or has gastric bypass/other major surgery planned to occur during the 10 month trial
boolean
C0192398 (UMLS CUI [1])
C0017125 (UMLS CUI [2])
C0017125 (UMLS CUI [3,1])
C1301732 (UMLS CUI [3,2])
C0679637 (UMLS CUI [4,1])
C1301732 (UMLS CUI [4,2])
Myocardial Infarction | Congestive heart failure New York Heart Association Classification | Chronic atrial fibrillation
Item
myocardial infarction within the last 2 years, current congestive heart failure with nyha class 2 or greater, or chronic atrial fibrillation
boolean
C0027051 (UMLS CUI [1])
C0018802 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0694539 (UMLS CUI [3])
Illness Clinical Significance | Chronic disease
Item
current clinically significant and/or chronic illness
boolean
C0221423 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0008679 (UMLS CUI [2])
Non-Steroidal Anti-Inflammatory Agents Regular
Item
takes regular courses of non-steroidal anti-inflammatory drugs (nsaids). if these medications are discontinued upon starting screening procedures and are not planned to be regularly used during the trial, the patient will be allowed to enter the study
boolean
C0003211 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
CORTICOSTEROIDS FOR SYSTEMIC USE Oral | CORTICOSTEROIDS FOR SYSTEMIC USE Suppository | CORTICOSTEROIDS FOR SYSTEMIC USE Injection | CORTICOSTEROIDS FOR SYSTEMIC USE Inhalation allowed | Topical corticosteroids allowed
Item
use of systemic corticosteroids (oral, suppository, injected). use of inhaled or topical corticosteroids is permitted
boolean
C3653708 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C3653708 (UMLS CUI [2,1])
C0038854 (UMLS CUI [2,2])
C3653708 (UMLS CUI [3,1])
C1828121 (UMLS CUI [3,2])
C3653708 (UMLS CUI [4,1])
C0205535 (UMLS CUI [4,2])
C0683607 (UMLS CUI [4,3])
C0304604 (UMLS CUI [5,1])
C0683607 (UMLS CUI [5,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial